From Approval to Access: Europe’s Next Health Imperative for Pharma

From Approval to Access: Europe's Next Health Imperative for Pharma

Despite EMA approvals, patients across Europe face delayed or no access to new medicines. This analysis examines the systemic barriers, the EU Pharma Package response, and the strategic implications for European pharma companies and investors. For BD teams and analysts weighing the competitiveness of pharmaceuticals in Europe, the widening gap between regulatory clearance and patient reach has become the continent's defining policy battleground.

Key Takeaways

• EMA approval does not guarantee patient access; national HTA and pricing systems create significant delays that undermine the value of centralized authorization.
• The EU Pharma Package and the EU HTA Regulation represent the most concerted policy response in two decades, but national implementation remains the critical variable.
• EFPIA's "Europe's Choice" campaign warns that without reform, European pharma companies risk becoming second-tier markets for innovation — BD teams and investors should track the EU pharmaceutical legislation timeline as a catalyst for sector re-rating.

What is driving Europe's approval-to-access gap?

The European Medicines Agency operates one of the most rigorous drug approval systems globally. Through its centralized procedure, the EMA grants marketing authorization valid across all EU member states in a single assessment. Yet that stamp of approval is increasingly hollow where it matters most: at the pharmacy counter and the hospital bedside. Patients across the continent face what a recent POLITICO analysis describes as inequitable and delayed access to new medicines, a problem that persists years after regulatory clearance.

The root cause is not scientific. The European Federation of Pharmaceutical Industries and Associations has argued through its EFPIA office and the "Europe's Choice" campaign that the bottleneck sits in the systems designed to facilitate access: fragmented national health technology assessments, prolonged pricing negotiations, and a lack of political will to prioritize patient access. These Efpia root causes include the reality that once the EMA says a medicine is safe and effective, each member state effectively starts its own evaluation from scratch, duplicating effort and adding months or years to the timeline. The industry has quantified the impact: according to EFPIA's Patients W.A.I.T. Indicator report, the average time from EMA approval to patient access across Europe stretches well beyond one year for some countries.

The political temperature is rising. The Polish presidency of the Council of the EU made health a centerpiece, convening the "Together for Europe's Health" conference under the banner strategic orientations and actions for public health. That event, described as one of the first major initiatives of the Polish presidency, brought together representatives from across the bloc and signaled that Europe's health ambition is returning to the political agenda. The featured answer from the debate captures the mood precisely: "We have a system where approved medicines are not readily available for patients: this is not a failure of science, but of the systems designed to facilitate access." Europe's health ambition is returning to the political agenda, and the approval-to-access gap is no longer an academic complaint — it is a front-burner policy problem.

How will the EU Pharma Package and HTA Regulation close the gap?

The European Commission's EU Pharma Package, proposed as a revision to the bloc's pharmaceutical legislation, is the most comprehensive regulatory overhaul in two decades. Its explicit goal is to reduce the time from EMA approval to patient access, particularly by rewarding companies that launch promptly across all member states and by streamlining regulatory procedures. The package is still working its way through the legislative process, and the final text remains subject to negotiation between the European Parliament and the Council. The EU pharmaceutical legislation timeline is a key watchpoint: the current compromise drafts include provisions linking regulatory data protection to timely launch, which could create winners among companies with broad commercial infrastructure and penalize those that rely on staggered rollouts.

Alongside the Pharma Package, the EU HTA Regulation — formally Regulation (EU) 2021/2282 — is designed to harmonize clinical evidence requirements for joint clinical assessments at the EU level. If successfully implemented, it could reduce duplication for European pharma companies that currently must submit different dossiers to each national HTA body. A recent analysis in PMC on what is needed to successfully implement the EU HTA Regulation emphasizes that building mutual trust, improving collaboration, and engaging all relevant stakeholders are essential. Communication, the authors note, is equally important: regulators, payers, and industry must speak a common language about what constitutes evidence of value. The joint clinical assessments will phase in from 2025 onward, starting with oncology products and advanced therapy medicinal products. For BD teams, this means that the window to prepare for harmonized EU-level evidence dossiers is closing fast.

The stakes are high. The EFPIA Europe's choice campaign, spearheaded by the EFPIA office in Brussels, warns that without urgent reform, Europe risks becoming a second-tier market for innovative medicines, with launches occurring first in the US and Asia and reaching European patients years later — if at all. The industry invests roughly 15% of revenue in R&D, and delayed access translates directly into lower return on innovation and weaker incentives to invest in European clinical development. At the European Health Summit in December 2025, the consensus was that Europe is at a crossroads where policy ambition collides with implementation reality. The EU Pharma Package is the clearest expression of that ambition — but its success depends on whether national governments are willing to cede some control over access timelines.

What are the implications for BD teams and investors?

For BD and corporate strategy teams at European pharma companies, the evolving legislative timeline creates clear strategic inflection points. Companies with strong early HTA strategies — those that invest in real-world evidence generation and engage with joint clinical assessments proactively — may gain competitive advantage as the HTA Regulation takes effect. The regulation's phased implementation, starting with oncology in 2025, means that BD teams must begin now to align pipeline assets with the new joint clinical assessment requirements. Companies that wait for the regulation to be fully in force will find themselves scrambling to retrofit their evidence generation plans.

Investors should watch two catalysts. First, the final shape of the EU Pharma Package: provisions linking regulatory data protection to timely launch across all member states could create a clear bifurcation between companies with broad European commercial infrastructure and those that rely on staggered rollouts. The current Council position includes a conditional 8+2+1 data protection period, with the additional years tied to launch in all member states within two years. Second, national implementation of the HTA Regulation: if major member states including Germany, France, and Italy integrate the joint clinical assessments into their own pricing and reimbursement processes, the timeline from approval to access could compress meaningfully. If they do not, the regulation becomes a paper exercise. The European Commission's implementation roadmap provides a timeline for this integration, and national transposition laws will be the key indicator.

The EFPIA office in Brussels has been lobbying intensively to shape the final legislation, arguing that the package must preserve incentives for innovation while accelerating access. BD teams should engage directly with the association's policy workstreams, particularly around the definition of "unmet medical need" and the conditions for regulatory data protection extensions. The "Europe's Choice" campaign has also emphasized the need for the EU to maintain a competitive research environment — a concern that has grown louder as the US Inflation Reduction Act and Asian clinical trial growth pull R&D investment away from Europe.

The approval-to-access gap is not a new problem, but it has reached a political tipping point. The Polish presidency's "Together for Europe's Health" conference, the EU Pharma Package negotiations, the phased rollout of the HTA Regulation — these are not isolated events. They are signals that Europe's policymakers have finally recognized that a strong regulatory agency is not enough if the medicines it approves gather dust on the shelf. For European pharma companies and their investors, the next two years will determine whether these policy instruments become genuine catalysts for faster patient access or another layer of bureaucracy. The answer will shape where the next generation of medicines is launched first — and whether Europe remains a viable home for pharmaceutical innovation.

Frequently Asked Questions

Related coverage

• EMA's CHMP Recommends Oral Wegovy Approval, Expanding Obesity Treatment Options in Europe
• Favipiravir Shipment to Europe Signals Hantavirus Preparedness Amidst Cruise Ship Outbreak
• EMA's United for Health Initiative at WorldPride 2026